Decitabine in Treating Patients With Myelofibrosis

PHASE2Active, not recruitingINTERVENTIONAL
Enrollment

21

Participants

Timeline

Start Date

September 29, 2004

Primary Completion Date

July 1, 2008

Study Completion Date

February 22, 2026

Conditions
Primary MyelofibrosisSecondary Myelofibrosis
Interventions
DRUG

Decitabine

Given SC

OTHER

Laboratory Biomarker Analysis

Correlative studies

Trial Locations (14)

21201

University of Maryland/Greenebaum Cancer Center, Baltimore

43210

Ohio State University Comprehensive Cancer Center, Columbus

46628

Northern Indiana Cancer Research Consortium, South Bend

46845

Fort Wayne Medical Oncology and Hematology Inc-Parkview, Fort Wayne

49085

Oncology Care Associates PLLC, Saint Joseph

53226

Medical College of Wisconsin, Milwaukee

60153

Loyola University Medical Center, Maywood

60201

NorthShore University HealthSystem-Evanston Hospital, Evanston

60426

Ingalls Memorial Hospital, Harvey

60637

University of Chicago Comprehensive Cancer Center, Chicago

61615

Illinois CancerCare-Peoria, Peoria

62526

Decatur Memorial Hospital, Decatur

62702

Central Illinois Hematology Oncology Center, Springfield

Southern Illinois University School of Medicine, Springfield

All Listed Sponsors
lead

National Cancer Institute (NCI)

NIH